In response to these challenges, the WHO updated its recommendations in 2018 to include Carbetocin (heat‐stable formulation) as a uterotonic option for PPH prevention, especially in settings where oxytocin quality cannot be guaranteed [10]. Here, OXT is linked to pulmonary arterial hypertension.